Optimizing Management of X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) with Novel Targeted Therapies

CME: 1.0

October 18, 2021
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This CME activity is designed to meet the educational needs of pediatric and adult endocrinologists, pediatricians, and other HCPs who may contribute to the multidisciplinary team, such as radiologists, pathologists, nurse practitioners, and physician assistants interested in increasing their knowledge regarding XLH and TIO, as well as to improve competence in diagnosing and treating these diseases.

Program Overview

This CME-accredited on-demand webinar was presented live as an independent satellite symposium at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting in early October. Dr. Signe Beck-Nielsen, a key opinion leader and specialist in hypophosphatemic rickets from Aarhus University Hospital in Denmark, covers the diagnosis and clinical presentation of XLH including best practices for management. Dr. Thomas Weber, an expert in tumor-induced osteomalacia from Duke University, addresses the diagnosis of TIO including surgical/non-surgical management and novel therapies for treatment that have the potential to improve patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the pathophysiological basis for symptom development in XLH and TIO
  • Identify clinical manifestations and diagnostic methods to make a timelier diagnosis of XLH and TIO
  • Assess recent developments in the treatment of these two FGF-23 linked disorders
  • Effectively integrate new evidence-based therapeutic strategies into clinical practice when managing patients with XLH and TIO

Post a comment to this article